Clinician: Patients with immune system disorders are usually treated with a class of drugs that, unfortunately, increase the patient's risk of developing osteoporosis, a bone-loss disease.
Conclusion (should = opinion)
Patients with immune system disorders should take this new drug (that enhances growth of new bone cells) in addition to the drug that helps to preserve existing bone.
Evidence (since)
Patients with immune system disorders usually get treated with drugs that increase the risk of osteoporosis, a bone-loss disease.
They take a drug that helps to preserve existing bone, and this new drug enhances the growth of new bone cells.
Evaluate
How could we potentially argue that these patients should not take this new drug that enhances the growth of new bone cells?
We'd probably have to either argue that it won't help them or that it will harm them.
Maybe enhancing new bone cells doesn't really do anything to lower the risk of developing osteoporosis (or lessen the severity of the disease once it's present).
Or, maybe this new drug has side effects that outweigh the positives. In particular, maybe it has side effects that are bad for people with immune system disorders, or maybe this new drug would have a harmful interaction with one of the existing drugs they're taking.
Goal
Look for an answer posing a question that could be answered in a way that would weaken the argument.
In other words,